1,320 Shares in Amgen Inc. $AMGN Bought by Snider Financial Group

Snider Financial Group purchased a new stake in Amgen Inc. (NASDAQ:AMGN) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 1,320 shares of the medical research company’s stock, valued at approximately $556,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Mosley Wealth Management raised its stake in Amgen by 12.0% in the 3rd quarter. Mosley Wealth Management now owns 1,486 shares of the medical research company’s stock worth $645,000 after purchasing an additional 159 shares in the last quarter. James T. Borello RIA increased its stake in shares of Amgen by 13.6% in the 3rd quarter. James T. Borello RIA now owns 209 shares of the medical research company’s stock valued at $88,000 after purchasing an additional 25 shares during the last quarter. Cyndeo Wealth Partners LLC raised its stake in Amgen by 13.5% during the third quarter. Cyndeo Wealth Partners LLC now owns 1,978 shares of the medical research company’s stock worth $834,000 after acquiring an additional 236 shares in the last quarter. Eagle Bay Advisors LLC increased its position in Amgen by 2.8% during the 3rd quarter. Eagle Bay Advisors LLC now owns 1,267 shares of the medical research company’s stock worth $534,000 after purchasing an additional 34 shares in the last quarter. Finally, Selective Wealth Management Inc. lifted its stake in shares of Amgen by 6.3% in the 3rd quarter. Selective Wealth Management Inc. now owns 1,710 shares of the medical research company’s stock valued at $742,000 after acquiring an additional 102 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Insider Buying and Selling at Amgen

In other news, SVP Rachna Khosla sold 2,000 shares of the stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total value of $825,140.00. Following the completion of the sale, the senior vice president directly owned 6,404 shares of the company’s stock, valued at $2,642,098.28. This represents a 23.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Nancy Grygiel sold 2,970 shares of the business’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the sale, the senior vice president owned 7,340 shares in the company, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 6,222 shares of company stock worth $2,540,926 over the last quarter. 0.85% of the stock is owned by company insiders.

Amgen Price Performance

NASDAQ:AMGN traded down $1.54 during trading hours on Friday, hitting $432.49. 2,567,027 shares of the company’s stock traded hands, compared to its average volume of 3,127,974. The firm has a market cap of $233.82 billion, a P/E ratio of 26.88, a P/E/G ratio of 3.18 and a beta of 0.41. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. The business’s fifty day simple moving average is $415.54 and its two-hundred day simple moving average is $374.76. Amgen Inc. has a 52 week low of $288.00 and a 52 week high of $447.03.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The business had revenue of $10.05 billion for the quarter, compared to analysts’ expectations of $9.43 billion. During the same quarter in the prior year, the firm earned $6.02 earnings per share. The firm’s revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, research analysts anticipate that Amgen Inc. will post 22.94 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 21st were given a dividend of $2.52 per share. The ex-dividend date of this dividend was Friday, August 21st. This represents a $10.08 annualized dividend and a dividend yield of 2.3%. Amgen’s dividend payout ratio is presently 62.65%.

Analyst Ratings Changes

Several analysts recently weighed in on AMGN shares. HSBC cut shares of Amgen from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $445.00 to $425.00 in a research note on Thursday, September 10th. Guggenheim decreased their target price on Amgen from $388.00 to $378.00 and set a “neutral” rating for the company in a research report on Tuesday. Barclays upped their price objective on shares of Amgen from $360.00 to $380.00 and gave the stock an “equal weight” rating in a report on Friday, August 14th. Morgan Stanley cut their target price on Amgen from $362.00 to $359.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 7th. Finally, Robert W. Baird upped their price objective on shares of Amgen from $215.00 to $230.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have issued a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $387.93.

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.